How Gene Therapy Delivers a Working Gene
This is a sample post so you can see the layout and grid filled in. Replace
it with your first real article using the template in src/templates/.
Gene therapy treats disease by adding, replacing, or silencing genetic instructions inside a patient’s cells. The idea is simple to state and hard to execute: the gene itself is only half the problem — getting it safely into the right cells is the other half, and it is where much of the field’s engineering effort goes [1].
The vehicle is the hard part
A therapeutic gene has to reach the correct tissue, get inside the cell, and stay active long enough to matter. Adeno-associated virus (AAV) vectors have become a workhorse for this because they are relatively safe and can be engineered to favor particular tissues — though they carry real limits on cargo size and can trigger an immune response [2].
Switching the gene on
Delivery is not the finish line. Once inside, the gene needs the right regulatory sequences so it is expressed at a useful level in the right cell type — too little does nothing, too much can be harmful. Tuning that expression is as much a part of the design as the gene itself.
Where this series goes next
Future posts will unpack each stage — vector choice, targeting, expression control, and the safety data behind approved therapies — with references to the primary literature throughout.
Discussion
Comments are powered by Giscus and will appear here once configured.